What is Andexxa (andexanet alfa) used for and why?

Andexxa: What It Is Used For and Why

Andexxa (andexanet alfa) is a specific reversal agent used to reverse the anticoagulant effects of the Factor Xa inhibitors apixaban and rivaroxaban in patients experiencing life-threatening or uncontrolled bleeding. 1

Mechanism of Action

Andexanet alfa is a recombinant modified human Factor Xa protein that acts as a decoy molecule. It binds to Factor Xa inhibitors in the bloodstream, sequestering them away from their target and thereby rapidly reversing their anticoagulant effect. The drug lacks enzymatic activity due to substitution of the active site serine with alanine and cannot incorporate into the clotting cascade itself. 2

Primary Indications

Andexanet is FDA-approved specifically for patients taking apixaban or rivaroxaban who develop:

• Life-threatening bleeding
• Uncontrolled bleeding requiring urgent reversal 1

The most common bleeding scenarios where andexanet is used include:

• Intracranial hemorrhage (69% of cases) - the predominant indication
• Gastrointestinal bleeding (23-26% of cases) 2

Why It Works

In clinical trials, andexanet demonstrated rapid and profound reversal of anticoagulation:

• 92-94% reduction in anti-Factor Xa activity within minutes of administration for both apixaban and rivaroxaban 2
• 80-82% of patients achieved excellent or good hemostatic efficacy at 12 hours after treatment 2, 3
• The effect lasts approximately 4 hours during the infusion period 2

Dosing Strategy

Andexanet is administered as an IV bolus followed by a 2-hour infusion, with two regimens available 4, 1:

Low Dose (400 mg bolus + 480 mg infusion):

• Rivaroxaban ≤10 mg taken <8 hours prior
• Apixaban ≤5 mg taken <8 hours prior
• Any dose taken ≥8 hours prior

High Dose (800 mg bolus + 960 mg infusion):

• Rivaroxaban >10 mg taken <8 hours prior
• Apixaban >5 mg taken <8 hours prior
• Unknown dose or timing

Critical Safety Considerations

The major concern with andexanet is thrombotic risk. The FDA includes a black box warning about serious and life-threatening adverse events 1:

• Thrombotic events occur in approximately 10% of patients within 30 days 2
• These include arterial and venous thromboembolism, myocardial infarction, ischemic stroke, cardiac arrest, and sudden death 1
• Notably, thrombotic events occurred predominantly in patients who did NOT restart anticoagulation after reversal 2
• Real-world data from the Netherlands suggests potentially lower thrombotic rates (4.6%) than reported in clinical trials 5

30-day mortality is substantial at 14-34%, though this reflects the severity of the underlying bleeding rather than drug toxicity per se 2, 3, 5

Important Limitations

• Andexanet is NOT indicated for edoxaban or betrixaban, though high-dose regimens are sometimes used off-label 4
• The drug has NOT been proven to improve clinical outcomes (morbidity/mortality) - FDA approval was based on surrogate endpoints (anti-Xa activity reduction) under accelerated approval 1
• No data support giving a second dose - efficacy and safety of repeat dosing are unknown 1
• Duration of reversal is limited to approximately 4 hours, after which anti-Xa activity may return 2

Clinical Decision-Making Algorithm

When to use andexanet:

1. Confirm patient is taking apixaban or rivaroxaban (check medication list)
2. Verify life-threatening or uncontrolled bleeding is present (intracranial hemorrhage, hemodynamically unstable GI bleeding)
3. Determine timing and dose of last Factor Xa inhibitor dose
4. Select appropriate andexanet dose regimen based on above
5. Administer within 18 hours of last anticoagulant dose for optimal effect 2

When NOT to use andexanet:

• Minor bleeding controllable with local measures
• Bleeding in patients on dabigatran (use idarucizumab instead) 2
• Patients with recent thrombotic events require careful risk-benefit assessment given prothrombotic risk

Alternative Approaches

If andexanet is unavailable, four-factor prothrombin complex concentrate (4F-PCC) or activated PCC can be used as alternatives, though these are non-specific reversal agents 4. Activated charcoal may be considered if the Factor Xa inhibitor was ingested within 2-4 hours 4.

Post-Reversal Management

Anticoagulation should be restarted when medically appropriate to minimize thrombotic risk, as most thrombotic events occurred in patients who never resumed anticoagulation 2. The timing depends on achieving hemostasis and the patient's underlying thrombotic risk profile.